ImmunityBio (NASDAQ:IBRX – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.11, Zacks reports.
ImmunityBio Price Performance
Shares of ImmunityBio stock opened at $3.29 on Monday. The stock has a market capitalization of $2.29 billion, a P/E ratio of -3.58 and a beta of 0.94. ImmunityBio has a one year low of $2.28 and a one year high of $10.53. The business’s 50 day simple moving average is $3.02 and its two-hundred day simple moving average is $3.74.
Analyst Ratings Changes
A number of research analysts have commented on the stock. BTIG Research started coverage on shares of ImmunityBio in a research report on Friday, January 10th. They set a “buy” rating and a $6.00 price target on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $30.00 target price on shares of ImmunityBio in a report on Friday.
ImmunityBio Company Profile
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Read More
- Five stocks we like better than ImmunityBio
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- 4 Blockchain Stocks That Aren’t Coinbase
- What does consumer price index measure?
- These 3 Tech Stocks Are Gaining Steam After NVIDIA’s Report
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- These S&P 500 Stocks Have Low P/E Ratios — Time to Buy?
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.
